Modeling studies on the role of vitamins B1 (thiamin), B3 (nicotinamide), B6 (pyridoxamine), and caffeine as potential leads for the drug design against COVID-19

J Mol Model. 2022 Nov 7;28(12):380. doi: 10.1007/s00894-022-05356-9.

Abstract

In response to the COVID-19 pandemic, and the lack of effective and safe antivirals against it, we adopted a new approach in which food supplements with vital antiviral characteristics, low toxicity, and fast excretion have been targeted. The structures and chemical properties of the food supplements were compared to the promising antivirals against SARS-COV-2. Our goal was to exploit the food supplements to mimic the topical antivirals' functions but circumventing their severe side effects, which has limited the necessary dosage needed to exhibit the desired antiviral activity. On this line, after a comparative structural analysis of the chemicals mentioned above, and investigation of their potential mechanisms of action, we selected caffeine and some compounds of the vitamin B family and further applied molecular modeling techniques to evaluate their interactions with the RDB domain of the Spike protein of SARS-CoV-2 (SC2Spike) and its corresponding binding site on human ACE-2 (HssACE2). Our results pointed to vitamins B1 and B6 in the neutral form as potential binders to the HssACE2 RDB binding pocket that might be able to impair the SARS-CoV-2 mechanism of cell invasion, qualifying as potential leads for experimental investigation against COVID-19.

Keywords: COVID-19; Caffeine; Docking; Molecular dynamic simulations; Vitamin B.

MeSH terms

  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology
  • COVID-19 Drug Treatment*
  • Caffeine / pharmacology
  • Drug Design
  • Humans
  • Molecular Docking Simulation
  • Niacinamide
  • Pandemics
  • Pyridoxamine
  • SARS-CoV-2
  • Thiamine / metabolism
  • Vitamins

Substances

  • Pyridoxamine
  • Thiamine
  • Caffeine
  • Niacinamide
  • Antiviral Agents
  • Vitamins